VALJUVANT CORPORATION

GLENVIEW, IL, 60026

Subcontracting experience

3 records from government sources. Past participation is not evidence of current teaming interest.

Role	Agency	Description	Vehicle	Obligated	Action date	Period
Subcontractor	Department of Health and Human Services	IN THIS PROJECT, WE PROPOSE TO DEVELOP A NEW TYPE OF ADJUVANTED VACCINE THAT BOTH ACTIVATES AND LIMITS THE INNATE IMMUNE RESPONSE. IN PRELIMINARY WORK, WE SHOWED THAT ADDING MOLECULES THAT ALTER THE SIGNALING OF THE NF-􀈛􀀥 AND IRF PATHWAY IN COMBINATION WITH A WELL-CHARACTERIZED TLR AGONIST RESULTED IN NEAR-ZERO SYSTEMIC INFLAMMATION WHILE MAINTAINING MINIMAL LOCAL INFLAMMATION. AT THE SAME TIME, ADDITION OF THIS COMPOUND, PME-564, INCREASED AND MODIFIED ANTIBODY RESPONSES FOR SEVERAL COMMERCIAL VACCINES – MOST NOTABLY FLUZONE. IN THIS WORK, WE PROPOSE TO FURTHER DEVELOP THIS COMPOUND, PME-564, ALONGSIDE A VACCINE, TO FIND A SINGLE ADJUVANT FORMULATION WHICH CAN BE USED IN AN IMPROVED FLU VACCINE. WE HAVE TWO GOALS: (1) FIND OPTIMIZED VACCINE FORMULATIONS THAT EFFECTIVELY LOWER SYSTEMIC INFLAMMATION AND ASSOCIATED SIDE EFFECTS WHILE BOOSTING ANTIBODY RESPONSES. PAIRING THESE FORMULATIONS WITH THE HIGHEST PERFORMING VACCINE PLATFORM TO DEVELOP VACCINE CANDIDATES. (2) TEST THESE VACCINE CANDIDATES FOR PERFORMANCE, TOXICITY AND SAFETY USING MICE TO IDENTIFY A CANDIDATE FOR TRANSITION TO PHASE I TESTING. THIS NEW APPROACH ADDRESSES A LIMITATION IN CURRENT ADJUVANT TECHNOLOGY. ADJUVANTS TRANSITIONING OUT OF BASIC DISCOVERY HAVE LIMITED METHODS TO CONTROL EXCESS INFLAMMATION IN THE FORM OF INCREASED CYTOKINES – REPRESENTED BY EXCESS TNF-􀄮􀀃􀁄􀁑􀁇􀀃􀀬􀀯-6 PRODUCTION. A PRIMARY EXAMPLE ARE TLR7/8 AGONISTS, WHICH HAVE BEEN EFFECTIVE IN VACCINES AGAINST MANY DISEASES BUT HAVE STRUGGLED WITH FORMULATION AND THE UNPREDICTABILITY OF SYSTEMIC INFLAMMATION AND TOXICITY.2–8 FORMULATIONS DO HELP ADDRESS THIS PROBLEM TO SOME EXTENT, BUT THEY DO NOT ADDRESS THE FUNDAMENTAL ACTIVITY OF THE COMPOUND WHICH GENERATES A LARGE INFLAMMATORY RESPONSE AT THE CELLULAR LEVEL. OUR APPROACH DIRECTLY TARGETS THE PATHWAY THAT CAUSES THIS EXCESSIVE AND OFTEN SYSTEMIC INFLAMMATION AND REDUCES IT. THE ADDED BENEFIT IS THAT BECAUSE THE MODULATION OCCURS INDEPENDENT OF THE AGONIST, IT CAN PROVIDE AN ADDED BENEFIT NOT JUST TO A SPECIFIC AGONIST, BUT TO ANY VACCINE BEARING TLR7/8 AGONISTS. THE RESULT IS COUNTER-INTUITIVE, BUT EMPIRICALLY VERIFIED, A BROAD INCREASE IN ANTIBODY RESPONSES FOR MANY VACCINES. THE ABILITY TO INDEPENDENTLY LIMIT IMMUNOTOXICITY ALSO OFFERS A UNIQUE OPPORTUNITY IN ADJUVANT DEVELOPMENT AS IT IS POSSIBLE THAT WE CAN INCLUDE MORE OF THE PRR AGONIST TO INCREASE ACTIVITY WHILE LIMITING ITS DAMAGING INFLAMMATORY RESPONSE. THE OPPORTUNITY TO HAVE CONTROL OF INFLAMMATION INDEPENDENT OF ADJUVANTICITY OFFERS A GREAT DEAL OF PROMISE FOR FUTURE VACCINES, HOWEVER THIS WILL REQUIRE THE DEVELOPMENT OF NEW MOLECULAR ENTITIES. THE CHALLENGE IN FORMULATING THIS UNIQUE COMBINATION OF MOLECULES IS THAT THE MODULATOR HAS NO INHERENT ACTIVITY WITHOUT THE PRESENCE OF THE TLR7/8 AGONIST. THE RESULT IS A SYSTEM THAT REQUIRES BOTH COMPONENTS TO BE DELIVERED IN PROXIMITY AND WITH CONTROLLED DOSAGE. AS WELL, EXPERIMENTS IN FORMULATION, DOSAGE, AND CONCENTRATION WILL PROVIDE ESSENTIAL INFORMATION FOR DEFINING HOW IMMUNE-MODULATORS SUCH AS PME-564 ARE CONSIDERED IN USE IN VACCINE FORMULATIONS. OUR PRIMARY OBJECTIVE IS TO DEVELOP AN ADJUVANT FORMULATION THAT INCREASES THE NEUTRALIZING IGG LEVELS AND DURABILITY OF THOSE LEVELS FOR A PLATFORM FLU VACCINE WHILE MINIMIZING THE INFLAMMATORY EFFECTS UPON INJECTION. OUR SECONDARY OBJECTIVE IS TO DEVELOP A NOVEL DERIVATIVE OF IMMUNOMODULATORY COMPOUND PME-564 􀀋􀀥􀁄􀁉􀁈􀁗􀁌􀁑􀁌􀁅􀀌􀀃 AS A BROAD-SPECTRUM VACCINE ENHANCING EXCIPIENT THAT CAN BE USED AS PART OF MULTIPLE FORMULATIONS. TO IMPROVE THE OUTCOME OF THE FORMULATION AND TO DEVELOP A NOVEL DERIVATIVE OF PME-564 􀀋􀀥􀁄􀁉􀁈􀁗􀁌􀁑􀁌􀁅􀀌, WE WILL EXPLORE THE MECHANISM OF A SERIES OF CHEMICALLY SYNTHESIZED DERIVATIVES, OPTIMIZE THEIR STRUCTURE AND FORMULATION, AND TEST THEM AS ADJUVANTS WITH MULTIPLE FLU VACCINATION PLATFORMS. THESE VACCINE CANDIDATES WILL THEN BE TESTED FOR SAFETY, TOXICITY, AND THE ABILITY TO PROVIDE PROTECTION IN MOUSE CHALLENGE BEFORE BEING USED IN HIGHER AN AWD104281 (SUB00001235) Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541512 Parent award performance state: IL Parent award description: DEVELOPMENT OF VACCINES FOR INFLUENZA USING AN IMMUNO-MODULATOR ADJUVANT AND MULTI-PLATFORM APPROACH View parent award on USAspending	—	$975,341	Mar 12, 2026	— – —
Subcontractor	Department of Health and Human Services	IN THIS PROJECT, WE PROPOSE TO DEVELOP A NEW TYPE OF ADJUVANTED VACCINE THAT BOTH ACTIVATES AND LIMITS THE INNATE IMMUNE RESPONSE. IN PRELIMINARY WORK, WE SHOWED THAT ADDING MOLECULES THAT ALTER THE SIGNALING OF THE NF-􀈛􀀥 AND IRF PATHWAY IN COMBINATION WITH A WELL-CHARACTERIZED TLR AGONIST RESULTED IN NEAR-ZERO SYSTEMIC INFLAMMATION WHILE MAINTAINING MINIMAL LOCAL INFLAMMATION. AT THE SAME TIME, ADDITION OF THIS COMPOUND, PME-564, INCREASED AND MODIFIED ANTIBODY RESPONSES FOR SEVERAL COMMERCIAL VACCINES – MOST NOTABLY FLUZONE. IN THIS WORK, WE PROPOSE TO FURTHER DEVELOP THIS COMPOUND, PME-564, ALONGSIDE MRNA VACCINES TO FIND A SINGLE ADJUVANT FORMULATION THAT CAN BE USED IN AN IMPROVED H5N1 VACCINE. WE HAVE TWO GOALS: (1) IDENTIFY A FORMULATION CANDIDATE THAT CAN BE RAPIDLY ADMIXED WITH EITHER CURRENT QUADRIVALENT FLU VACCINES OR MRNA VACCINES. PAIRING THESE FORMULATIONS WITH THE HIGHEST PERFORMING VACCINE PLATFORM TO DEVELOP VACCINE CANDIDATES. IMPROVING REACTOGENICITY, REDUCING DOSAGE, AND INCREASING DURABILITY OF EACH VACCINE. (2) RAPIDLY TESTING THESE CANDIDATES FOR COMPATIBILITY WITH COMMERCIAL VACCINE SYSTEMS AND PRE-CLINICAL PANDEMIC FLU VACCINES, DETERMINING AN APPROPRIATE TOXICITY AND SAFETY PROFILE FOR BOTH THE INDEPENDENT AND MIXED FORMULATION. THIS NEW APPROACH ADDRESSES A LIMITATION IN CURRENT ADJUVANT TECHNOLOGY. ADJUVANTS TRANSITIONING OUT OF BASIC DISCOVERY HAVE LIMITED METHODS TO CONTROL EXCESS INFLAMMATION IN THE FORM OF INCREASED CYTOKINES – REPRESENTED BY EXCESS TNF-􀄮􀀃􀁄􀁑􀁇􀀃􀀬􀀯-6 PRODUCTION. THE FOCUS OF THIS SUPPLEMENTAL PROGRAM WILL BE THE COFORMULATION OF THESE MOLECULES WITH MRNA VACCINES, SPECIFICALLY IN THE CONTEXT OF PANDEMIC FLU. FORMULATIONS DO HELP ADDRESS THIS PROBLEM TO SOME EXTENT, BUT THEY DO NOT ADDRESS THE FUNDAMENTAL ACTIVITY OF THE COMPOUND, WHICH GENERATES A LARGE INFLAMMATORY RESPONSE AT THE CELLULAR LEVEL. OUR APPROACH DIRECTLY TARGETS THE PATHWAY THAT CAUSES THIS EXCESSIVE AND OFTEN SYSTEMIC INFLAMMATION AND REDUCES IT. THE ADDED BENEFIT IS THAT BECAUSE THE MODULATION OCCURS INDEPENDENTLY OF THE AGONIST, IT CAN PROVIDE AN ADDED BENEFIT NOT JUST TO A SPECIFIC AGONIST BUT TO ANY H5N1, QUADRIVALENT, OR MRNA FLU VACCINE. THE RESULT IS COUNTER-INTUITIVE BUT EMPIRICALLY VERIFIED, A BROAD INCREASE IN ANTIBODY RESPONSES FOR THESE VACCINES. AS WELL, EXPERIMENTS IN FORMULATION, DOSAGE, AND CONCENTRATION WILL PROVIDE ESSENTIAL INFORMATION FOR DEFINING HOW IMMUNE-MODULATORS SUCH AS PME-564 ARE CONSIDERED IN USE IN VACCINE FORMULATIONS. WE WILL ALSO EXPLORE THE USE OF OUR IMMUNOMODULATOR IN THE CONTEXT OF DOSE SPARING FOR PANDEMIC FLU VACCINES. IF NEEDED, SEPARATE VIALS OF IMMUNOMODULATOR CAN BE CO-MIXED ON SITE OF VACCINATION WHICH WILL ENABLE DOSE SPARING FOR AVAILABLE VACCINES. WE WILL EXPLORE MAXIMAL AND MINIMAL DOSES OF MRNA IN COMBINATION WITH OUR IMMUNOMODULATORS TO SELECT THE BEST BALANCE BETWEEN DURABILITY, IMMUNOGENICITY, AND REACTOGENICITY. OUR PRIMARY OBJECTIVE IS TO DEVELOP AN ADJUVANT FORMULATION THAT INCREASES THE NEUTRALIZING IGG LEVELS AND DURABILITY OF THOSE LEVELS FOR A PLATFORM OF MRNA VACCINES WITH A FOCUS ON H5N1 FLU SYSTEMS WHILE MINIMIZING THE INFLAMMATORY EFFECTS UPON INJECTION. OUR SECONDARY OBJECTIVE IS TO DEVELOP A NOVEL DERIVATIVE OF IMMUNOMODULATORY COMPOUND PME-564 􀀋􀀥􀁄􀁉􀁈􀁗􀁌􀁑􀁌􀁅􀀌􀀃􀁄􀁖􀀃􀁄􀀃􀁅􀁕􀁒􀁄􀁇-SPECTRUM VACCINE ENHANCING OR DOSE SPARING EXCIPIENT THAT CAN BE USED AS PART OF MULTIPLE FORMULATIONS. TO IMPROVE THE OUTCOME OF THE FORMULATION AND TO DEVELOP A NOVEL DERIVATIVE OF PME-􀀘􀀙􀀗􀀃􀀋􀀥􀁄􀁉􀁈􀁗􀁌􀁑􀁌􀁅􀀌􀀏􀀃􀁚􀁈􀀃 WILL EXPLORE THE MECHANISM OF A SERIES OF CHEMICALLY SYNTHESIZED DERIVATIVES, OPTIMIZE THEIR STRUCTURE AND FORMULATION, AND TEST THEM AS ADJUVANTS WITH MULTIPLE FLU VACCINATION PLATFORMS. THESE VACCINE CANDIDATES WILL THEN BE TESTED FOR SAFETY, TOXICITY, AND THE ABILITY TO PROVIDE PROTECTION IN MOUSE CHALLENGE BEFORE BEING USED IN HIGHER ANIMAL MODELS. AWD104281 (SUB00001383) Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541512 Parent award performance state: IL Parent award description: DEVELOPMENT OF VACCINES FOR INFLUENZA USING AN IMMUNO-MODULATOR ADJUVANT AND MULTI-PLATFORM APPROACH View parent award on USAspending	—	$500,000	Oct 15, 2025	— – —
Subcontractor	Department of Health and Human Services	3.1 SCOPE IN THIS PROJECT, WE PROPOSE TO DEVELOP NEW IMMUNE-ENHANCING FORMULATIONS BY DISCOVERING AND OPTIMIZING SMALL MOLECULE MODULATORS THAT IMPROVE INNATE IMMUNE ACTIVATION TO SUPPORT ENHANCED T-CELL RESPONSES DURING VACCINATION. BUILDING ON PRELIMINARY WORK THAT IDENTIFIED PME-564 AS A POTENT MODULATOR OF NF RELATED COMPOUNDS THAT ACHIEVE AN OPTIMAL BALANCE OF IMMUNE ACTIVATION AND SAFETY. THESE COMPOUNDS WILL BE TESTED IN MULTIPLE FORMULATION TYPES TO ASSESS THEIR ABILITY TO POTENTIATE VACCINEINDUCED T-CELL RESPONSES WITHOUT INDUCING EXCESSIVE INFLAMMATION. WE HAVE TWO GOALS: (1) IDENTIFY A FORMULATION CANDIDATE THAT CAN BE RAPIDLY ADMIXED WITH EITHER CURRENT QUADRIVALENT VACCINES OR VACCINES. PAIRING THESE FORMULATIONS WITH THE HIGHEST PERFORMING VACCINE PLATFORM TO DEVELOP VACCINE CANDIDATES. IMPROVING REACTOGENICITY, REDUCING DOSAGE, AND INCREASING DURABILITY OF EACH VACCINE. PRE-CLINICAL NEXT-GENERATION VACCINES VACCINES, DETERMINING AN APPROPRIATE TOXICITY AND SAFETY PROFILE FOR BOTH THE INDEPENDENT AND MIXED FORMULATION. THIS NEW APPROACH ADDRESSES A LIMITATION IN CURRENT ADJUVANT TECHNOLOGY. ADJUVANTS TRANSITIONING OUT OF BASIC DISCOVERY HAVE LIMITED METHODS TO CONTROL EXCESS INFLAMMATION IN THE FORM OF INCREASED CYTOKINES – REPRESENTED BY EXCESS TNF 6 PRODUCTION. THE FOCUS OF THIS SUPPLEMENTAL PROGRAM WILL BE THE CO-FORMULATION OF THESE MOLECULES WITH VACCINES, SPECIFICALLY IN THE CONTEXT OF NEXT-GENERATION VACCINES. FORMULATIONS DO HELP ADDRESS THIS PROBLEM TO SOME EXTENT, BUT THEY DO NOT ADDRESS THE FUNDAMENTAL ACTIVITY OF THE COMPOUND, WHICH GENERATES A LARGE INFLAMMATORY RESPONSE AT THE CELLULAR LEVEL. OUR APPROACH DIRECTLY TARGETS THE PATHWAY THAT CAUSES THIS EXCESSIVE AND OFTEN SYSTEMIC INFLAMMATION AND REDUCES IT. THE ADDED BENEFIT IS THAT BECAUSE THE MODULATION OCCURS INDEPENDENTLY OF THE AGONIST, IT CAN PROVIDE AN ADDED BENEFIT NOT JUST TO A SPECIFIC AGONIST BUT TO ANY , QUADRIVALENT, OR FLU VACCINE. THE RESULT IS COUNTER-INTUITIVE BUT EMPIRICALLY VERIFIED, A BROAD INCREASE IN ANTIBODY RESPONSES FOR THESE VACCINES. AS WELL, EXPERIMENTS IN FORMULATION, DOSAGE, AND CONCENTRATION WILL PROVIDE ESSENTIAL INFORMATION FOR DEFINING HOW IMMUNE-MODULATORS SUCH AS PME-564 ARE CONSIDERED IN USE IN VACCINE FORMULATIONS. WE WILL ALSO EXPLORE THE USE OF OUR IMMUNOMODULATOR IN THE CONTEXT OF DOSE SPARING FOR NEXTGENERATION VACCINES VACCINES. IF NEEDED, SEPARATE VIALS OF IMMUNOMODULATOR CAN BE CO-MIXED ON SITE OF VACCINATION WHICH WILL ENABLE DOSE SPARING FOR AVAILABLE VACCINES. WE WILL EXPLORE MAXIMAL AND MINIMAL DOSES OF IN COMBINATION WITH OUR IMMUNOMODULATORS TO SELECT THE BEST BALANCE BETWEEN DURABILITY, IMMUNOGENICITY, AND REACTOGENICITY. OUR PRIMARY OBJECTIVE IS TO DEVELOP AN ADJUVANT FORMULATION THAT INCREASES THE T-CELL RESPONSES AND DURABILITY OF THOSE LEVELS FOR A PLATFORM OF VACCINES WITH A FOCUS ON FLU SYSTEMS WHILE MINIMIZING THE INFLAMMATORY EFFECTS UPON INJECTION. OUR SECONDARY OBJECTIVE IS TO DEVELOP A NOVEL DERIVATIVE OF IMMUNOMODULATORY COMPOUND PME-564 AND RELATED DERIVATIVES AS A BROAD-SPECTRUM VACCINE ENHANCING OR DOSE SPARING EXCIPIENT THAT CAN BE USED AS PART OF MULTIPLE FORMULATIONS. TO IMPROVE THE OUTCOME OF THE FORMULATION AND TO DEVELOP A NOVEL DERIVATIVE OF PME-564 AND RELATED DERIVATIVES, WE WILL EXPLORE THE MECHANISM OF A SERIES OF CHEMICALLY SYNTHESIZED DERIVATIVES, OPTIMIZE THEIR STRUCTURE AND FORMULATION, AND TEST THEM AS ADJUVANTS WITH MULTIPLE FLU VACCINATION PLATFORMS. THESE VACCINE CANDIDATES WILL THEN BE TESTED FOR SAFETY, TOXICITY, AND THE ABILITY TO PROVIDE PROTECTION IN MOUSE CHALLENGE BEFORE BEING USED IN HIGHER ANIMAL MODELS. AWD100509 (SUB00001386) Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541714 Parent award performance state: IL Parent award description: TO IDENTIFY NOVEL ADJUVANT CANDIDATES THAT CAN BE USED TO AUGMENT THE EFFICACY OF HUMAN VACCINES. View parent award on USAspending	—	$214,999	May 12, 2025	— – —

Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.

Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.